Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 17

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 17
---
 share, representing the difference between the assumed public offering price per share of Common Stock and accompanying common warrant and our pro forma net tangible book value per share as of March 31, 2025. To the extent outstanding options or warrants to purchase our Common Stock are exercised, new investors may incur further dilution. For more information on the dilution you may experience as a result of investing in this offering, see the section of this prospectus entitled “ Dilution.”

Stockholders will likely suffer substantial dilution when certain provisions in the common warrants are utilized.

If the common warrants are exercised by way of an alternative cashless exercise, assuming receipt of Stockholder Approval, such exercising holder will receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash rather than a cashless exercise of the common warrant and (ii) 3.0. Accordingly, it is highly unlikely that a holder of the common warrants would wish to pay an exercise price in cash to receive one share of Common Stock when they could instead choose the alternative cashless exercise option and pay no cash to receive three shares of Common Stock. As a result, we will likely not receive, and do not expect to receive, any additional funds upon the exercise of the common warrants. If the alternative cashless exercise provision is utilized, our stockholders may suffer substantial dilution.

On the Adjustment Date, the exercise price of the common warrants will be reduced to the greater of the Floor Price and the lowest daily dollar volume-weighted average price during the period beginning two full trading days prior to the Adjustment Date and ending on the 10th trading day after the Adjustment Date. Upon any such resulting adjustment of the exercise price of the common warrants, the number of shares of Common Stock issuable under the common warrants will be increased such that the aggregate exercise price of a common warrant (adjusted for any exercises by a holder prior to this adjustment) will remain unchanged following such adjustment. As a result, the aggregate number of shares of Common Stock underlying all of the common warrants may increase from 15,000,000 up to 150,000,000 (in each case, based on an assumed public offering price of $0.80 per share), assuming full adjustment of the exercise price to the Floor Price and before giving effect to the “alternative cashless exercise” provision. Assuming full adjustment of the exercise price to the Floor Price, the aggregate number of shares of Common Stock issuable upon the exercise of all